Skip to main content
. Author manuscript; available in PMC: 2014 Dec 30.
Published in final edited form as: Curr Pharm Des. 2012;18(27):4187–4196. doi: 10.2174/138161212802430486

Fig. (2). Tag-free ILYd4 has higher RTX-mediated CDC effect on B-cell malignancy cells than His-tagged ILYd4.

Fig. (2)

(A) The expression of CD59 on the cell surface of ARH-77 RL, and RTX-resistant cell lines RamosR51.2. Grey and white curves represent the staining with IgG plus FITC conjugated secondary Ab and with anti-hCD59 Ab plus FITC conjugated secondary Ab, respectively. (B) CDC effect on B-cell malignancy cells in the presence of the serial dilutions of the tag-free and His-tagged ILYd4. (C) ED50s of tag-free and His-tagged ILYd4 for ARH-77 RL, and Ramos51.2. Result are mean ± SD of three independent experiments. *P<0.01 v.s. His-tagged ILYd4.